Timing of initiation of oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation comparing posterior and anterior circulation strokes.
Acute stroke
atrial fibrillation
stroke recurrence
Journal
European stroke journal
ISSN: 2396-9881
Titre abrégé: Eur Stroke J
Pays: England
ID NLM: 101688446
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
12
2019
accepted:
02
06
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
ppublish
Résumé
The aim of this study in patients with acute posterior ischaemic stroke (PS) and atrial fibrillation (AF) was to evaluate (1) the risks of recurrent ischaemic event and severe bleeding and (2) these risks in relation with oral anticoagulant therapy (OAT) and its timing. Patients with PS were prospectively included; the outcome events of these patients were compared with those of patients with anterior stroke (AS) which were taken from previous registries. The primary outcome was the composite of stroke recurrence, transient ischaemic attack, symptomatic systemic embolism, symptomatic cerebral bleeding and major extracranial bleeding occurring within 90 days from acute stroke. A total of 2470 patients were available for the analysis: 473 (19.1%) with PS and 1997 (80.9%) with AS. Over 90 days, 213 (8.6%) primary outcome events were recorded: 175 (8.7%) in patients with AS and 38 (8.0%) in those with PS. In patients who initiated OAT within 2 days, the primary outcome occurred in 5 out of 95 patients (5.3%) with PS compared to 21 out of 373 patients (4.3%) with AS (OR 1.07; 95% CI 0.39-2.94). In patients who initiated OAT between days 3 and 7, the primary outcome occurred in 3 out of 103 patients (2.9%) with PS compared to 26 out of 490 patients (5.3%) with AS (OR 0.54; 95% CI 0.16-1.80). our findings suggest that, when deciding the time to initiate oral anticoagulation, the location of stroke, either anterior or posterior, does not predict the risk of outcome events. Patients with PS or AS and AF appear to have similar risks of ischaemic or haemorrhagic events at 90 days with no difference concerning the timing of initiation of OAT.
Identifiants
pubmed: 33598556
doi: 10.1177/2396987320937116
pii: 10.1177_2396987320937116
pmc: PMC7856592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
374-383Informations de copyright
© European Stroke Organisation 2020.
Références
AJNR Am J Neuroradiol. 1993 Jan-Feb;14(1):3-13
pubmed: 8427107
Lancet Neurol. 2019 Jan;18(1):117-126
pubmed: 30415934
Int J Stroke. 2017 Aug;12(6):589-596
pubmed: 28730948
Eur Stroke J. 2019 Sep;4(3):198-223
pubmed: 31984228
J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1614-20
pubmed: 25899158
Cerebrovasc Dis. 2017;43(3-4):152-160
pubmed: 28088807
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
BMC Res Notes. 2017 Nov 13;10(1):592
pubmed: 29132407
Neurology. 1996 Nov;47(5):1125-35
pubmed: 8909417
Cerebrovasc Dis. 2001;11(4):311-6
pubmed: 11385210
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
J Neurol Sci. 2012 Feb 15;313(1-2):142-6
pubmed: 21945462
J Stroke Cerebrovasc Dis. 2010 Sep-Oct;19(5):393-7
pubmed: 20472466
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396
Stroke. 2015 Aug;46(8):2175-82
pubmed: 26130094
PLoS Med. 2007 Oct 16;4(10):e296
pubmed: 17941714
J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):33-7
pubmed: 20802030
J Am Heart Assoc. 2017 Nov 29;6(12):
pubmed: 29220330
Lancet Neurol. 2013 Oct;12(10):989-98
pubmed: 24050733
Stroke. 2001 Jun;32(6):1318-22
pubmed: 11387493
J Stroke Cerebrovasc Dis. 2019 Mar;28(3):710-718
pubmed: 30501979
Neuroepidemiology. 2009;33(1):12-6
pubmed: 19299902
J Cardiovasc Electrophysiol. 2003 Apr;14(4):443-5
pubmed: 12741724
Stroke. 2019 Aug;50(8):2093-2100
pubmed: 31221054
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Stroke. 2008 Aug;39(8):2249-56
pubmed: 18535273
J Neurol Sci. 2006 May 15;244(1-2):143-50
pubmed: 16530226